Lawrence Blonde

17.1k total citations · 9 hit papers
181 papers, 10.3k citations indexed

About

Lawrence Blonde is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Lawrence Blonde has authored 181 papers receiving a total of 10.3k indexed citations (citations by other indexed papers that have themselves been cited), including 158 papers in Endocrinology, Diabetes and Metabolism, 40 papers in Molecular Biology and 37 papers in Surgery. Recurrent topics in Lawrence Blonde's work include Diabetes Treatment and Management (129 papers), Diabetes Management and Research (118 papers) and Metabolism, Diabetes, and Cancer (40 papers). Lawrence Blonde is often cited by papers focused on Diabetes Treatment and Management (129 papers), Diabetes Management and Research (118 papers) and Metabolism, Diabetes, and Cancer (40 papers). Lawrence Blonde collaborates with scholars based in United States, United Kingdom and Canada. Lawrence Blonde's co-authors include John B. Buse, Julio Rosenstock, Eduard Montanya, Giorgio Sesti, Wolfgang E. Schmidt, Jason Brett, Marcin Zychma, Guillermo E. Umpierrez, Paul S. Jellinger and Daniel Einhorn and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Investigation.

In The Last Decade

Lawrence Blonde

174 papers receiving 9.8k citations

Hit Papers

Liraglutide once a day versus exenatide twice a day for t... 2009 2026 2014 2020 2009 2009 2018 2020 2018 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
    2009 1.2k citations John B. Buse, Julio Rosenstock et al. profile →
  2. Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
    2009 707 citations John B. Buse, Lawrence Blonde et al. Diabetes Care profile →
  3. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
    2018 454 citations Lawrence Blonde et al. profile →
  4. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary
    2020 411 citations Alan J. Garber, Yehuda Handelsman et al. Endocrine Practice profile →
  5. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary
    2018 377 citations Alan J. Garber, Lawrence Blonde et al. Endocrine Practice profile →
  6. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary
    2017 327 citations Alan J. Garber, Lawrence Blonde et al. Endocrine Practice profile →
  7. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange
    2017 279 citations Lawrence Blonde et al. Diabetes Care profile →
  8. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary
    2019 225 citations Alan J. Garber, Lawrence Blonde et al. Endocrine Practice profile →
  9. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update
    2023 206 citations Lawrence Blonde et al. Endocrine Practice profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lawrence Blonde United States 49 8.2k 3.3k 2.9k 1.6k 993 181 10.3k
Vanita R. Aroda United States 49 7.3k 0.9× 3.2k 1.0× 2.1k 0.7× 1.4k 0.9× 1.6k 1.6× 166 10.2k
Yehuda Handelsman United States 44 6.4k 0.8× 2.0k 0.6× 3.3k 1.1× 832 0.5× 948 1.0× 113 9.3k
Sanjoy K. Paul Australia 30 7.9k 1.0× 2.5k 0.8× 2.0k 0.7× 823 0.5× 918 0.9× 106 10.7k
David M. Kendall United States 38 5.3k 0.6× 2.2k 0.7× 3.0k 1.0× 1.0k 0.7× 985 1.0× 108 7.4k
Thomas Först Germany 46 4.7k 0.6× 2.3k 0.7× 2.2k 0.8× 682 0.4× 958 1.0× 228 7.5k
Alan J. Garber United States 51 9.1k 1.1× 3.9k 1.2× 3.8k 1.3× 1.8k 1.2× 2.1k 2.1× 142 13.3k
Daniel Einhorn United States 27 5.8k 0.7× 2.0k 0.6× 1.6k 0.6× 738 0.5× 891 0.9× 43 7.4k
Jorge Luiz Gross Brazil 51 5.8k 0.7× 2.3k 0.7× 2.3k 0.8× 796 0.5× 1.5k 1.6× 234 10.5k
George Grunberger United States 52 6.9k 0.8× 3.2k 1.0× 3.5k 1.2× 818 0.5× 1.4k 1.4× 161 10.9k
Guntram Schernthaner Austria 60 6.2k 0.8× 2.9k 0.9× 2.7k 0.9× 924 0.6× 1.7k 1.7× 227 11.0k

Countries citing papers authored by Lawrence Blonde

Since Specialization
Citations

This map shows the geographic impact of Lawrence Blonde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Blonde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Blonde more than expected).

Fields of papers citing papers by Lawrence Blonde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence Blonde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Blonde. The network helps show where Lawrence Blonde may publish in the future.

Co-authorship network of co-authors of Lawrence Blonde

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence Blonde. A scholar is included among the top collaborators of Lawrence Blonde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence Blonde. Lawrence Blonde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Riddle, Matthew C., Lawrence Blonde, Hertzel C. Gerstein, et al.. (2019). Diabetes Care Editors’ Expert Forum 2018: Managing Big Data for Diabetes Research and Care. Diabetes Care. 42(6). 1136–1146. 8 indexed citations
5.
Raccah, D., Bruno Guerci, Mayank Ajmera, et al.. (2019). Clinical implications of prolonged hyperglycaemia before basal insulin initiation in type 2 diabetes patients: An electronic medical record database analysis. Endocrinology Diabetes & Metabolism. 2(3). e00061–e00061. 2 indexed citations
6.
Blonde, Lawrence, Luigi Meneghini, Xuejun Peng, et al.. (2018). Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. Diabetes Therapy. 9(3). 1347–1358. 51 indexed citations
7.
Home, Philip, et al.. (2017). Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study. Diabetes Obesity and Metabolism. 20(4). 921–929. 3 indexed citations
8.
Bailey, Robert A., Ujjwala Vijapurkar, Gary Meininger, Marcia F.T. Rupnow, & Lawrence Blonde. (2014). Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.. PubMed. 20(13 Suppl). s296–305. 16 indexed citations
9.
Garber, Alan J., Lawrence Blonde, Zachary T. Bloomgarden, Yehuda Handelsman, & Samuel Dagogo‐Jack. (2013). The Role of Bromocriptine-Qr in the Management of Type 2 Diabetes Expert Panel Recommendations. Endocrine Practice. 19(1). 100–106. 23 indexed citations
10.
Gaziano, J. Michael, Anthony H. Cincotta, Aaron I. Vinik, et al.. (2012). Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects. Journal of the American Heart Association. 1(5). e002279–e002279. 75 indexed citations
11.
Birkeland, K. I., Itamar Raz, S Gough, et al.. (2011). Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes. Diabetologia. 54. 6 indexed citations
12.
Atkin, Stephen L., Steve Baín, S Gough, et al.. (2011). Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes. Diabetologia. 54. 8 indexed citations
13.
Freemantle, Nick, Beverley Balkau, N Danchin, et al.. (2009). Cardiovascular (CV) Risk Evaluation in People with Type 2 Diabetes (T2D) on Insulin Therapy (CREDIT) Study-CV Disease and CV Risk at Baseline. UCL Discovery (University College London). 1 indexed citations
14.
Marre, Michel, N Danchin, Nick Freemantle, et al.. (2009). Cardiovascular Risk Evaluation in People with Type 2 Diabetes (T2D) on Insulin Therapy (CREDIT) Study: Patterns of Initial Prescription of Insulin and Associated Changes in Oral Glucose-Lowering Drug (OGLD) Therapy. UCL Discovery (University College London). 2 indexed citations
15.
Kennedy, Laurence & Lawrence Blonde. (2009). Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleveland Clinic Journal of Medicine. 76(12 suppl 5). S4–S11. 34 indexed citations
16.
17.
Freemantle, Nick, et al.. (2006). The availability of inhaled human insulin may lead to a greater acceptance of insulin therapy in European type 2 diabetes patients failing on diet and/or oral agent therapy. UCL Discovery (University College London). 1 indexed citations
18.
Blonde, Lawrence. (2000). Disease management approaches to type 2 diabetes.. PubMed. 9(8 Suppl). 18–23; discussion 24. 5 indexed citations
19.
Garber, Alan M., W S Browner, Ernest L. Mazzaferri, et al.. (1996). Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Annals of Internal Medicine. 124(5). 515–517. 103 indexed citations
20.
Blonde, Lawrence, et al.. (1976). Hypoglycemia: the "undisease".. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 69(10). 1261–5. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vanita R. Aroda Breakdown of academic impact, for papers by Yehuda Handelsman Breakdown of academic impact, for papers by Sanjoy K. Paul Breakdown of academic impact, for papers by David M. Kendall Breakdown of academic impact, for papers by Thomas Först Breakdown of academic impact, for papers by Alan J. Garber Breakdown of academic impact, for papers by Daniel Einhorn Breakdown of academic impact, for papers by Jorge Luiz Gross Breakdown of academic impact, for papers by George Grunberger Breakdown of academic impact, for papers by Guntram Schernthaner
Rankless by CCL
2026